Page last updated: 2024-12-06

18-crown-6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

18-crown-6 is a macrocyclic polyether with the formula (CH2CH2O)6. It is a colorless solid that is soluble in organic solvents. 18-crown-6 is a well-known example of a crown ether. 18-crown-6 is prepared by the reaction of ethylene glycol with a base, such as sodium hydroxide. The reaction is typically carried out in a solvent, such as tetrahydrofuran or dioxane. The resulting product is then purified by distillation or recrystallization. 18-crown-6 forms stable complexes with a variety of metal cations, including alkali metal cations. The complexation of metal cations by 18-crown-6 is driven by the electrostatic interactions between the oxygen atoms of the crown ether and the metal cation. These complexes are often used as catalysts in organic reactions and as carriers for metal cations in biological systems. 18-crown-6 is also used as a phase transfer catalyst and as a sensor for metal ions. 18-crown-6 is a versatile compound that has found a wide range of applications in chemistry, biology, and materials science.'

18-crown-6 : A crown ether that is cyclooctadecane in which the carbon atoms at positions 1, 4, 7, 10, 13 and 16 have been replaced by oxygen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID28557
CHEMBL ID155204
CHEBI ID32397
SCHEMBL ID1119
MeSH IDM0065265

Synonyms (68)

Synonym
EN300-17608
3,6,9,12,15,18-hexaoxacyclooctadecan
brn 1619616
ccris 3587
1,4,7,10,13,16-hexanoxacyclooctadecane
einecs 241-473-5
nsc 159836
1,4,7,10,13,16-hexaoxacyclooctadecane
CHEBI:32397 ,
ethylene oxide cyclic hexamer
17455-13-9
1,7,10,13,16-hexaoxacyclooctadecane
nsc-159836
18-crown-6
wln: t-18-o do go jo mo potj
1,7,10,13,16-hexanoxacyclooctadecane
nsc159836
18-crown-6 ether
18-crown-6, 99%
18-crown-6, >=99.0%
18-crown 6-ether
AKOS000268988
1,4,7,10,13,16hexaoxa-cyclooctadecane
CHEMBL155204 ,
1,4,7,10,13,16-hexaoxacyclooctadecane;1,4,7,10,13,16-hexaoxacyclooctadecane (18-crown-6)
A811662
unii-63j177nc5b
63j177nc5b ,
5-19-12-00601 (beilstein handbook reference)
hexaoxacyclooctadecane
1,4,7,10,13,16-hexoxacyclooctadecane
BP-10155
FT-0607264
18-crown ether-6
SCHEMBL1119
o4b ,
1,4,7, 10,13,16-hexaoxacyclooctadecane
18-crown -6
18-crown 6
1,4,7,10,13,16-hexaoxacyclooctadecan
18crown-6
18-crown-6ether
18-crown6
18--crown-6 ether
18-crown-6-ether
1,4,7,10,13,16-hexaoxacycloocta-decane
18 -crown-6
1,4,7,10,13,16-hexaoxacyclo-octadecane
DTXSID7058626
Q-200102
crown ether 18-crown-6
AC-29207
mfcd00005113
F0001-0636
CS-D1202
18-crown-6, purum, >=99.0% (gc)
18-crown-6, pkg of 25 g
18-crown-6, for ion chromatography, >=99.0% (gc)
SY002250
1,4,7,10,13,16-hexaoxacyclooctadecane (18-crown-6)
BCP24491
Q3238432
18-crown-6 ether, 97+ percent
AMY25595
STL185678
18-c-6
[18]crown-6
bdbm50530238

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully applied to study the pharmacokinetic of PVP-I in rabbits after vaginal administration."( Optimization and validation of an ion-pair RP-HPLC-UV method for the determination of total free iodine in rabbit plasma: application to a pharmacokinetic study.
Cui, L; Fan, G; Wang, S; Wen, J; Zhou, T, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" All signs faded after four days when dosage levels were kept constant, but returned when the dose was doubled."( Behavioral and neuropharmacological toxicology of the macrocyclic ether 18-crown-6.
Conroy, WJ; Gad, SC; McKelvey, JA; Turney, KA, 1978
)
0.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
phase-transfer catalystA catalyst that facilitates the migration of a reactant from one phase into another phase where reaction occurs.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
crown etherCrown compounds containing only oxygen as coordinating atom.
saturated organic heteromonocyclic parent
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)IC50 (µMol)15.00000.16004.292110.0000AID1614589; AID1614590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID280245Antiproliferative activity against H460 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1614585Stabilization of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as formation of TTR tetramer band formation at 100 mM after 4 mins by SDS-PAGE analysis based glutaraldehyde cross-linking assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614590Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as BC50 for ANS binding to TTR at 5 uM in presence of 150 mM K+ by fluorescence-based assay (Rvb = 3 uM)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID280247Antiproliferative activity against MiaPaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID280246Antiproliferative activity against HeLa cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1614589Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as BC50 for ANS binding to TTR at 100 mM in presence of 150 mM Na+ by fluorescence-based assay (Rvb = 3 uM)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614579Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 6 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID280249Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID280248Antiproliferative activity against SW620 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1614581Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 2 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID50775In vitro lethal dose of compound against Eimeria tenella in chicken kidney cell cultures1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Anticoccidial activity of crown polyethers.
AID611986Antibacterial activity against Bacillus subtilis after 70 mins2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.
AID1614580Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 20 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (194)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (6.19)18.7374
1990's14 (7.22)18.2507
2000's58 (29.90)29.6817
2010's92 (47.42)24.3611
2020's18 (9.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.73 (24.57)
Research Supply Index5.29 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index84.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other195 (98.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]